Compounds of formula (I):
Compounds of formula (I):
Compounds of formula (I):
as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 419/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
2.
SYSTEMS, DEVICES, AND METHODS FOR MEASURING COMPONENTS
Systems for measuring a drug container closure member such as a syringe stopper and related methods and devices are disclosed. A system for measuring a drug container closure member may include a measurement device configured to measure at least one characteristic of the drug container closure member. The system may further include a positioning device or fixture having a base and an arm configured to extend from the base. Furthermore, the arm may be configured to hold the drug container closure member in at least one position allowing the measurement device to measure the at least one characteristic of the drug container closure member.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
G01B 5/00 - Measuring arrangements characterised by the use of mechanical techniques
G01B 11/02 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness
G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
The disclosure relates to compositions and methods for treating DLL3-expressing cancers by administration of an anti-DLL3 antigen-binding agent (e.g., tarlatamab) to a subject once every four weeks (Q4W).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided herein are FLT1 binding proteins, as well as related nucleic acids, vectors, host cells, pharmaceutical compositions and kits. The present disclosure additionally provides methods of treating a subject in need thereof, including subjects in need of treatment for PAD, CLI, ANOCA, or heart failure (HF). Further provided are methods of increasing VEGF-mediated and/or PlGF-mediated signal transduction in a subject, which, in turn, increases blood flow, capillary density, capillary or coronary growth, and/or cardiac perfusion in the subject. The present disclosure further provides methods of reducing blood pressure and risk of heart failure in a subject. In exemplary embodiments, each of the methods comprise administering to the subject a pharmaceutical composition of the present disclosure. In various embodiments, the pharmaceutical composition comprises a FLT1 binding protein of the present disclosure.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 39/00 - Medicinal preparations containing antigens or antibodies
5.
SEQUENTIAL DIGESTION OF POLYPEPTIDES FOR MASS SPECTROMETRIC ANALYSIS
The disclosed methods are directed to preparing polypeptides for multi-attribute analysis. The polypeptides are optionally denatured, reduced, and/or alkylated before being subjected to a first digestion. Following the first digestion the large and small fragments resulting from the digestion are separated from each other. A second digestion is then performed on the larger of the fragments. All of the fragments from the two digestions are then analyzed chromatographically, electrophoretically, or spectrometrically, or a combination of these methods. The methods are especially useful for the preparation of therapeutic polypeptides for analysis, especially those that are not easily cleaved.
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
Provided herein are recombinant T-cell receptors (TCRs) that can selectively recognize the MAGE-A4-derived peptide GVYDGEEHSV or KVEEHVVRV when presented by HLA-A*0201 sufficiently to activate the recombinant T cell. TCRs provided herein were thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissue and for alloreactivity.
The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (BCRP) substrate. e.g., rosuvastatin.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations;pharmaceutical preparations for the treatment of cancer;pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders;pharmaceutical preparations for the treatment of the respiratory system;pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders;pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis;pharmaceutical preparations for the treatment of autoimmune diseases and disorders;pharmaceutical preparations for the treatment of asthma and other breathing disorders;pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
The present invention provides provide a pharmaceutical composition comprising a bispecific antigen binding molecule at an increased concentration, wherein the composition comprises at least one buffer agent, at least one saccharide; and at least one stabilizing agent selected from Ethylenediaminetetraacetic acid (EDTA), Diethylenetriaminepentetic acid (DTP A), and citric acid in order to stabilize the bispecific antigen-binding agent even at higher concentration.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
41 - Education, entertainment, sporting and cultural services
Goods & Services
educational services, namely development and dissemination of educational materials in the field of autoimmune diseases and disorders; conducting seminars in the field of autoimmune diseases and disorders
20.
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
The present invention provides MDM2 inhibitor compounds of Formula I,
The present invention provides MDM2 inhibitor compounds of Formula I,
wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/153 - Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
Provided herein is a method for treating DLL3-expressing cancers using an anti-DLL3 antigen-binding protein administered subcutaneously. The anti-DLL3 antigen-binding protein comprises the amino acid sequence of SEQ ID NO: 13 and the amino acid sequence of SEQ ID NO: 22, and may be administered to a subject once every two weeks (Q2W), once every three weeks (Q3W), or once every four weeks (Q4W).
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
22.
PREDICTIVE MODEL TO EVALUATE PROCESSING TIME IMPACTS
Systems and methods for evaluating impacts of processing time of a process (such as a bioprocess) can include (a) obtaining a model trained using historical bioprocess data, (b) determining, by applying input to the model, predicted output that would result when operating the bioprocess in accordance with the input, wherein either: (i) the input includes a processing time and the predicted output includes a product quality, or (ii) the input includes a product quality parameter and the predicted output includes a processing time, and (c) displaying or storing the values of the predicted output. Further aspects include receiving the input as user input from a user. Still further aspects include presenting the predicted output to the user via a graphical user interface.
A method for improving the harvest or purification of a target protein such as a biologic or biosimilar is provided. The method improves conventional harvest/purification methodologies by adding a chromatography step, such as a mixed-mode or ion exchange chromatography step, towards the end of the polishing phase of harvest/purification, after conventional chromatographic polishing steps such as protein A or ion exchange chromatography steps have been completed and the resultant eluate subjected to filtration, such as ultrafiltration/diafiltration. The surprising result of returning to chromatographic polishing after filtration is that all forms of high molecular weight products are reduced, facilitating the purification of target protein sufficient to meet government regulations, such as Quality Target Protein Profiles.
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising (a) administering to the patient a therapeutically effective amount of sotorasib for 14 to 48 days (“an induction period”), and (b) administering to the patient a therapeutically effective amount of sotorasib and a therapeutically effective amount of an anti-PD 1 antibody or an anti-PD-L1 antibody after the induction period for the duration of a combination period.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
25.
METHODS OF DETECTING OFF-TARGET BINDING OF PROTEINS
The present invention relates to methods of detecting off-target binding of proteins such as antibodies. Said methods are useful in identifying proteins that are likely to have more rapid clearance in vivo compared to proteins that do not have (or they have less) off-target binding.
Methods of producing Minute Mouse Virus (MMV) stock are described herein. Methods of producing xenotropic murine leukemia virus (xMuLV) stock are described herein.
The disclosure provides methods of purifying a target protein, e.g., an antibody, from a host cell such as a mammalian cell using purification protocols incorporating harvest recovery operations comprising a continuous solids discharge disc stack centrifugation step followed by flocculation and depth filtration steps. The protein harvest methods of the disclosure recover high yields of purified target protein from perfusion cultures having a packed cell volume of greater than or equal to 16%, using an unconventional yet effective process.
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
29.
APPARATUSES, SYSTEMS AND METHODS FOR PLUNGER-STOPPER DEPTH MEASUREMENT IN PRE-FILLED SYRINGES
Automatic prefilled syringe inspection systems, apparatus and methods are provided. The automatic syringe inspection systems, apparatus and methods may determine a plunger depth within a syringe that has been pre-filled with a medication. The plunger depth may be based on digital image data that is representative of a silhouette of at least a portion of a tubular vessel and at least a portion of a plunger within the tubular vessel.
G01F 11/02 - Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
OPTICAL SYSTEMS AND PLATFORMS FOR SIMULTANEOUSLY ANALYZING MULTIPLE SOLUTION PROPERTIES
Disclosed herein are optical systems and platforms for the simultaneous assessment of one or more properties of a sample, e.g., a biomolecule-containing pharmaceutical composition, including, e.g., aggregation, phase separation, and/or viscosity, as well as methods of using the same.
G01N 11/02 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by measuring flow of the material
G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
32.
A CELL-BASED PLATFORM FOR IDENTIFYING NATIVE PROTEIN-PROTEIN INTERACTIONS IN MAMMALIAN DISPLAY LIBRARIES
The present disclosure is directed to methods of identifying a binding protein from a library of cell surface expressed binding proteins having a target protein binding specificity. These methods comprise providing a first cell population, where the first cell population comprises a library of cell surface expressed binding proteins; and providing a second cell population, where cells of the second population express the target protein. The first and second cell populations are contacted under conditions suitable for the target protein to bind to a corresponding surface expressed binding protein, if the binding protein is present in the library. A binding interaction between a target protein and surface expressed binding protein induces trogocytosis between cells of the binding interaction. Trogocytosis is assessed between cells after the contacting step, and a surface expressed binding protein of the library having the target protein binding specificity is identified if trogocytosis is detected.
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
33.
SYNTHETIC PROCESSES FOR PHARMACEUTICALLY ACTIVE COMPOUNDS
A process for making a compound of Compound 1 having the following structure: or a salt thereof, said method comprising contacting 2-fluorobenzoic acid (compound 1) with an iron catalyst and a phosphine ligand in the presence of a methylaluminum reagent and 1,2-dichloropropane.
C07C 51/60 - Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides into halides with the same carboxylic acid part
C07C 51/353 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by isomerisationPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by change of size of the carbon skeleton
This disclosure provides a stable cyclodextrin free carfilzomib formulation in aqueous solution which is suitable for injection, a kit comprising said cyclodextrin free carfilzomib formulation, and methods for preparation of said cyclodextrin free carfilzomib. Such formulation, kit and methods substantially increase the solubility and stability of the carfilzomib in aqueous solution and facilitate both their manufacture and administration.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to methods and cell lines for increasing yield of proteins such as antibodies, and also methods of producing proteins in modified mammalian cells.
A bubble trap system configured for use with a single use centrifuge system includes a bubble trap configured to be disposed on a suction side of a centrifuge feed pump. The bubble trap includes a body having a first end with an inlet, a second end with an outlet, a fluid flow path disposed between the inlet and the outlet, a first area within the body, a second area within the body, and an opening between the first and second ends of the body. A chamber is coupled to and in fluid communication with the opening of the body. A first eccentric reducer is coupled to the inlet and has an inlet tube in fluid communication with the first area of the body, and a second eccentric reducer is coupled to the outlet and has an outlet tube in fluid communication with the second area of the body.
The present disclosure relates to the treatment of (a) biochemical recurrence of nonmetastatic castration-sensitive prostate cancer, (b) localized prostate cancer, or (c) metastatic hormone-sensitive prostate cancer with an anti-STEAP1 antigen binding protein.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events.
40.
MULTISPECIFIC MOLECULES FOR CLEARANCE OF IMMUNOGLOBULINS IN THE TREATMENT OF AUTOANTIBODY-INDUCED DISEASES
The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events.
A syringe assembly includes a syringe having a barrel and a needle hub disposed at a distal end of the syringe and a needle shield including an inner surface and a cavity for receiving the needle hub. The inner surface of the needle shield engaging an outer surface of the needle hub to form a sealing interface therebetween and removably couple the needle hub and the needle shield when the needle shield is disposed on the syringe. In some examples, the sealing interface comprises at least one contoured feature configured to limit or reduce an amount of force required to remove the needle shield from the syringe.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A needle shield assembly includes a first needle shield at least partially made of a first material and having a proximal end and a distal end, the proximal end of the first needle shield including a cavity; and a second needle shield at least partially made of a second material, the second needle shield mechanically coupled with at least the proximal end of the first needle shield. Additionally, the second material of the second needle shield is harder than the first material of the first needle shield.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating cancer, immune, cardiovascular, metabolic and inflammatory diseases and conditions
The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods for mixing fluids including etanercept include providing a tank having an impeller with a 10 inch blade diameter disposed therein, filling a tank with a liquid composition comprising etanercept and one or more buffers to a level within the tank to cover the impeller, and operating the impeller to mix the liquid composition to a homogeneous state while maintaining a maximum shear stress imparted on the mixture of fluids at 125,000 s−1 or below.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
B01F 27/113 - Propeller-shaped stirrers for producing an axial flow, e.g. shaped like a ship or aircraft propeller
B01F 27/61 - Mixers with rotary stirring devices in fixed receptaclesKneaders with stirrers rotating about a horizontal or inclined axis about an inclined axis
B01F 27/71 - Mixers with rotary stirring devices in fixed receptaclesKneaders with stirrers rotating about a horizontal or inclined axis with propellers
A method for assessing transferability of a fill recipe includes collecting acceleration data of a needle of an off-line filler using an accelerometer, and collecting acceleration data of a needle of an online filler using another accelerometer. The method further includes calculating at least one of velocity, speed, or displacement data of the needle of each of the off-line filler and the online filler. The method also includes generating a graphical representation of at least one of the calculated velocity, speed, or displacement data of the needle of the off-line filler relative to the at least one of the calculated velocity, speed, or displacement data of the needle of the online filler by overlaying the at least one of the calculated velocity, speed, and displacement data to identify any data discrepancy. The method still further includes adjusting at least one parameter of the fill recipe for transferring.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
The present invention relates to mammalian cells modified to have reduced AEP protease activity. Such cells can be used for producing recombinant proteins.
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
58.
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The present disclosure provides methods for producing recombinant proteins (e.g., antibodies) in mammalian cell culture under conditions that limit filter fouling and enable robust recirculating tangential flow (RTF) filtration operation in perfusion processes in which the working volume is increased to a final working volume during the cell culture.
The invention provides a method for treating prurigo nodularis by administering an anti-OX40 or anti- OX40L inhibitor, and an article of manufacture with instructions for such use. In particular the invention relates to a dosage regiment wherein an anti-OX40 antibody is administered at a dose of between about 150 mg and 300 mg once every 4 weeks, with an additional loading dose of anti-OX40 antibody between about 150 mg and 300 mg at week 2.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A drug delivery device may include a housing having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include a guard moveably positioned adjacent to the opening and a plunger having a generally cylindrical body portion extending along a longitudinal axis of the container and at least one flange extending radially outwardly from the body portion, wherein the plunger is moveable toward the distal end of the container to expel a drug through the delivery member. The device may further include a plunger biasing member configured to urge the plunger toward the distal end of the container and a releaser member defining a guide configured to receive the at least one flange and an indicator configured to generate an audible signal indicating an end of drug delivery.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with
pharmaceutical preparations for treating oncology,
hematology, cardiovascular, metabolic and inflammatory
diseases and conditions. Injectors for medical purposes, namely, medical fluid
injectors.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed herein are engineered polypeptides having improved imine reductase (IRED) activity, the nucleotides that encode said engineered polypeptides, and methods for using said engineered polypeptides in a reduction of an imine to a chiral amine.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
65.
ARTIFICIAL INTELLIGENCE (AI) VALIDATION DATASET GENERATION SYSTEMS AND METHODS FOR GENERATING AI VALIDATION DATASETS FOR VALIDATING AI-BASED PROTEIN SEQUENCE MODELS
Artificial intelligence (Al) validation dataset generation systems and methods are described for generating Al validation datasets for validating Al-based protein sequence models. Such systems and methods include filtering a reference proteome dataset to generate a high completeness proteome data subset comprising reference proteomes. The high completeness proteome data subset is filtered to generate a protein confidence-based proteome data subset with reference proteomes above a protein confidence threshold. The plurality of protein sequences is clustered to generate a set of protein sequence clusters and a validation cluster subset is randomly allocated therefrom for creation of a protein sequence validation dataset. Validation metrics may then be generated by comparing (a) a set of predetermined values of the protein sequence validation dataset; and (b) the one or more predicted protein sequences as output by an Al-based protein sequence model.
Disclosed herein are compounds having activity as inhibitors of Werner Syndrome RecQ DNA helicase (WRN), pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to colorectal, endometrial, gastric and ovarian cancer. In particular, the disclosure provides compounds of Formula (A-I): (I), and pharmaceutically acceptable salts thereof, wherein the substituents are as described herein.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
INHBEINHBE gene. Methods of using such RNAi constructs to treat or prevent visceral obesity and diseases associated with visceral obesity, such as cardiovascular disease, are also described.
Disclosed herein are compounds having activity as inhibitors of Werner Syndrome RecQ DNA helicase (WRN), pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to colorectal, endometrial, gastric and ovarian cancer. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described herein.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
69.
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to treatment methods for prostate cancer using a combination of an anti-androgen compound and a T-cell engaging molecule that specifically binds to human prostate-specific membrane antigen (PSMA) and human CD3. In particular, the present invention relates to methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, in a patient in need thereof comprising administering to the patient one or more cycles of an anti-androgen compound in combination with a PSMA-targeted T-cell engaging molecule, wherein administration of the first dose of the anti-androgen compound is delayed relative to administration of the first therapeutic dose of the PSMA-targeted T-cell engaging molecule in the first cycle.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are methods of treating erosive hand osteoarthritis (OA) in a subject in need thereof, methods of reducing radiographic erosive progression, joint space narrowing, cartilage degradation, and/or bone formation in a subject in need thereof (e.g., a subject suffering from erosive hand OA), methods of inhibiting the development of new erosive joints in a subject in need thereof (e.g., a subject suffering from erosive hand OA), and methods of reducing pain in a subject with erosive hand OA. Also provided herein are uses of denosumab in the manufacture of a medicament adapted for use in a method described herein, as well as pharmaceutical compositions comprising denosumab for use in a method described herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Compositions comprising a monomer and a dimer of an anti-PCSK9 antibody such as evolocumab are described herein. Methods of determining the presence, absence, or amount of a dimer in a composition comprising evolocumab are described herein.
Provided herein are pharmaceutical compositions comprising Compound A, such as 1-40 wt% Compound A, wherein the pharmaceutical compositions are suitable for oral administration. In some embodiments, the disclosed compositions are suitable for high drug loading. The disclosed compositions are suitable for treating diseases or disorders responsive to inhibiting protein arginine methyltransferase 5 (PRMT5) (e.g., cancer).
The present invention provides a continuous upstream manufacturing process for the production of bispecific antibody products, which comprise at least two binding domains. The process comprises at least the steps of (i) providing in a perfusion bioreactor at least one mammalian cell culture, which is capable of expressing the bispecific antibody product, (ii) growing the mammalian cell culture at a first perfusion rate until a set point viable cell density is reached, and (iii) maintaining perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is kept below a threshold value. The bispecific antibody product is then subject to subsequent downstream processing. Moreover, the invention provides a bispecific antibody product produced by the continuous upstream manufacturing process.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
B01F 101/44 - Mixing of ingredients for microbiology, enzymology, in vitro culture or genetic manipulation
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris (3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris (3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).
This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
77.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates treating cancer, such as treating a solid tumor, by combining a bispecific molecule that simultaneously targets PD-L1 and 4-1BB, and a multispecific T cell engager molecule that targets CD3 and a Tumor Antigen.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Systems and methods for inspecting pharmaceutical product are disclosed. A controller connected to a multi-axis robotic arm may be used to automatically perform a process that includes agitating liquid in a vial using a multi-axis robotic arm, pausing agitation of the vial for inspection of the liquid, and releasing the vial from the multi-axis robotic arm. The liquid may be agitated by moving the vial through an agitation motion profile that includes at least two-dimensional motion of the vial around an axis according to programmed motion parameters used to control movement of one or more axes of the multi-axis robotic arm. The motion of the vial includes at least two nonparallel vectors to move the vial around an axis. Such motion may induce a swirling motion of the fluid that mimics the motion that may be used in a manual visual inspection process.
Provided herein are methods of separating diastereomers of a double-stranded oligonucleotide. In exemplary embodiments, the method comprises: (a) applying a sample comprising diastereomers of a double-stranded oligonucleotide to an anion exchange (AEX) chromatographic matrix, wherein each strand of the double-stranded oligonucleotide comprises at least one phosphorothioate internucleotide linkage; and (B) applying a mobile phase to the AEX chromatographic matrix to elute the diastereomers of the double-stranded oligonucleotide from the matrix, wherein the mobile phase comprises a buffer and an elution salt and has a pH of greater than 10.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
CNR1CNR1 gene. Methods of using such RNAi constructs to reduce visceral adiposity and treat or prevent obesity and obesity-related conditions, such as type 2 diabetes, fatty liver disease, steatohepatitis, and cardiovascular disease, are also described.
Systems and methods for characterizing a recipe of a syringe filling system can include (a) receiving a value of a plunger depth for a syringe, (b) receiving values of product parameters, (c) determining, by applying the value of the plunger depth and the values of the product parameters as inputs to a model, values of vacuum parameters of the syringe filling system for use when filling the syringe with a product having the values of the product parameters, and (d) displaying or storing the values of the vacuum parameters. Further aspects include characterizing a recipe of the syringe filling system for use with a second value of the plunger depth for a second syringe. Still further aspects include causing one or more vacuum devices of the syringe filling system to operate at the values of the vacuum parameters.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 31/02 - Filling, closing, or filling and closing, containers in chambers maintained under vacuum or superatmospheric pressure or containing a special atmosphere, e.g. of inert gas
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
Provided herein are methods of treating a cancer comprising a KRAS G12C mutation in a patient with active brain metastases, comprising administering sotorasib to the patient in amount effective to treat the cancer.
Provided herein are methods of separating peptides of an enzyme digestion which may be useful in analyzing a protein for post-translational modifications. In exemplary embodiments, the method comprises (a) applying a sample comprising enzyme-digested peptides of a protein to a multi-column liquid chromatography (MCLC) system comprising a first RPLC column in tandem with a second RPLC column, whereby digested peptides of the sample bind to the first and/or second RPLC column and (b) applying a mobile phase to the MCLC system to obtain eluted peptides, wherein the first RPLC column is (i) different from the second RPLC column, (ii) joined to the second RPLC column through a connector, and (iii) in fluid communication with the second RPLC column. Fluids applied flow from the first RPLC column to the second RPLC column through the connector without flowing through any intervening valves or diverters.
C07K 1/20 - Partition-, reverse-phase or hydrophobic interaction chromatography
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
G01N 30/46 - Flow patterns using more than one column
91.
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions
(2) Injectors for medical purposes, namely, medical fluid injectors
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions. Injectors for medical purposes, namely, medical fluid injectors.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions. Injectors for medical purposes, namely, medical fluid injectors.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions. Injectors for medical purposes, namely, medical fluid injectors.
96.
LOW PH PHARMACEUTICAL COMPOSITION COMPRISING T CELL ENGAGING ANTIBODY CONSTRUCTS
The present invention provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
97.
SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
useful for the synthesis of compounds that target KRAS G12C mutations, such as
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
useful for the synthesis of compounds that target KRAS G12C mutations, such as
Disclosed herein are methods for mitigating viscous fingering during cation exchange chromatography and reducing the number of peaks in a cation exchange chromatography isocratic elution profile.
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
Described herein are methods of treating a MTAP-null cancer in a patient in need thereof comprising administering (a) Compound A, or pharmaceutically acceptable salt thereof, at a total daily dose of 120 mg, 240 mg, 300 mg, 480 mg, 600 mg, 800 mg, 900 mg, 1200 mg, or 1600 mg; and (b) Compound B, or pharmaceutically acceptable salt thereof, at a total daily dose of 10 mg, 15 mg, 30 mg, or 60 mg.
This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
